We’re very excited to be launching our latest study and clinical trial, the ABATE study.

People with Down’s syndrome often develop dementia (Alzheimer’s) when they get older, which is caused by a build-up of a protein called Amyloid in the brain.

ACI-24.060 is a new treatment which is not yet on the market. It is designed to help reduce the level of a protein called Amyloid in the brain, and slow the loss of memory and other areas of thinking.

It is hoped that the vaccine will slow down the memory problems and other thinking difficulties that is caused by Alzheimer’s disease.

In this study, participants will either receive the vaccine or a dummy vaccine called a placebo. Neither the participant, their dependant, family and/or friends, nor study doctor and study team will know if the participant is taking the active vaccine or placebo injections.

The duration of participation in the trial will be approximately for 106 weeks. This includes a screening period of up to 6 weeks and a 74-week treatment period followed by a 26-week follow-up period. The main purpose of this study is to find out:

• If the study vaccine is safe and well tolerated
• If the study vaccine is able to stimulate a response in the body against Amyloid protein
• How the study vaccine works inside the body (mechanism of action)

The study is open to people with Down’s syndrome who are aged 35-50 years old.

If you’re interested in taking part and would like more information please contact Madelaine Smith at Madelaine.Smith9@cpft.nhs.uk